- A Family with Axenfeld-Rieger Syndrome: Report of the Clinical and Genetic Findings
-
Yang HJ, Lee YK, Joo CK, Moon JI, Mok JW, Park MH
- KMID: 2363769
- Korean J Ophthalmol.
- 2015 Aug;29(4):249-255.
- doi: 10.3341/kjo.2015.29.4.249
PURPOSE: To describe clinical findings in a Korean family with Axenfeld-Rieger syndrome. METHODS: A retrospective review of clinical data about patients with diagnosed Axenfeld-Rieger syndrome. Five affected members of the family... -
- CITED
-
- Close
- SHARE
-
- Close
- A Novel De Novo Pathogenic Variant in FOXF1 in a Newborn with Alveolar Capillary Dysplasia with Misalignment of Pulmonary Veins
-
Ma Y, Jang MA, Yoo HS, Ahn SY, Sung SI, Chang YS, Ki CS, Park WS
- KMID: 2419131
- Yonsei Med J.
- 2017 May;58(3):672-675.
- doi: 10.3349/ymj.2017.58.3.672
Alveolar capillary dysplasia with misalignment of pulmonary veins (ACD/MPV) is an autosomal dominant, fatal developmental disorder of the lungs, with a mortality rate of about 100%. ACD/MPV is caused by... -
- CITED
-
- Close
- SHARE
-
- Close
- In vitro effects of meloxicam on the number, Foxp3 expression, production of selected cytokines, and apoptosis of bovine CD25+CD4+ and CD25-CD4+ cells
-
Maslanka T, Jaroszewski JJ
- KMID: 1705513
- J Vet Sci.
- 2013 Jun;14(2):125-134.
- doi: 10.4142/jvs.2013.14.2.125
The purpose of this study was to evaluate the effect of meloxicam (MEL) on selected immune parameters of bovine CD25highCD4+, CD25lowCD4+, and CD25-CD4+ cells. Peripheral blood mononuclear cells (PBMCs) collected... -
- CITED
-
- Close
- SHARE
-
- Close
- Association of FOXJ1 polymorphisms with systemic lupus erythematosus and rheumatoid arthritis in Korean population
-
Li CS, Zhang Q, Lim MK, Sheen DH, Shim SC, Kim JY, Lee SS, Yun KJ, Moon HB, Chung HT, Chae SC
- KMID: 1091075
- Exp Mol Med.
- 2007 Dec;39(6):805-811.
The forkhead-box J1 (FOXJ1) transcription factor could suppress a spontaneous activation of T cells and B cells through an induction of IkappaBbeta that results in repression of NF-kappaB activity. In... -
- CITED
-
- Close
- SHARE
-
- Close
